• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Sensei Biotherapeutics Inc.

    12/4/25 4:18:32 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNSE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001797409
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Sensei Biotherapeutics, Inc.
    SEC File Number
    001-39980
    Address of Issuer
    1405 RESEARCH BLVD, SUITE 125
    ROCKVILLE
    MARYLAND
    20850
    Phone
    (240) 243-8000
    Name of Person for Whose Account the Securities are To Be Sold
    Cambrian BioPharma Inc
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    245 Summer Street
    Boston � MA � 02110
    584450901.00126129012/04/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/07/2021Open Market PurchaseN/ACheckbox not checked10004/07/2021Cash
    Common04/01/2021Open Market PurchaseN/ACheckbox not checked5004/01/2021Cash
    Common03/30/2021Open Market PurchaseN/ACheckbox not checked10003/30/2021Cash
    Common03/24/2021Open Market PurchaseN/ACheckbox not checked18703/24/2021Cash
    Common03/23/2021Open Market PurchaseN/ACheckbox not checked47503/23/2021Cash
    Common03/22/2021Open Market PurchaseN/ACheckbox not checked10903/22/2021Cash
    Common03/18/2021Open Market PurchaseN/ACheckbox not checked4103/18/2021Cash
    Common03/08/2021Open Market PurchaseN/ACheckbox not checked5003/08/2021Cash
    Common03/05/2021Open Market PurchaseN/ACheckbox not checked40003/05/2021Cash
    Common03/04/2021Open Market PurchaseN/ACheckbox not checked10003/04/2021Cash
    Common03/03/2021Open Market PurchaseN/ACheckbox not checked15003/03/2021Cash
    Common03/02/2021Open Market PurchaseN/ACheckbox not checked15003/02/2021Cash
    Common02/26/2021Open Market PurchaseN/ACheckbox not checked25002/26/2021Cash
    Common02/25/2021Open Market PurchaseN/ACheckbox not checked60002/25/2021Cash
    Common02/24/2021Open Market PurchaseN/ACheckbox not checked95002/24/2021Cash
    Common02/23/2021Open Market PurchaseN/ACheckbox not checked101502/23/2021Cash
    Common02/22/2021Open Market PurchaseN/ACheckbox not checked49002/22/2021Cash
    Common02/19/2021Open Market PurchaseN/ACheckbox not checked58902/19/2021Cash
    Common02/18/2021Open Market PurchaseN/ACheckbox not checked3802/18/2021Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/04/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Cristina Garcia, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Cambrian BioPharma Inc

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SNSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNSE

    DatePrice TargetRatingAnalyst
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/14/2024$5.00Overweight
    Stephens
    3/10/2022$12.00 → $10.00Overweight
    Piper Sandler
    7/1/2021$12.00Buy → Hold
    Berenberg
    6/29/2021$30.00 → $14.00Outperform → Perform
    Oppenheimer
    6/29/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SNSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

    VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi

    3/19/26 11:00:00 AM ET
    $ATOS
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435 shares of the Company's common stock in connection with their employment (collectively, the "Option Award"). The Option Award was granted as an inducement material to the individual entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Award has an exercise price of $29.37, which is equal to the closing price of Sensei's common stock on March 11, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the date of grant, wit

    3/17/26 6:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on February 19, 2026, Sensei's Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the Company's common stock in connection with their employment, including a grant to Anand Parikh of an option to purchase 1,239,305 shares of the Company's common stock in connection with his employment as Chief Operating Officer of the Company (collectively, the "Option Awards"). The Option Awards were granted as an inducement material to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Awards have an exercise price of $2

    2/25/26 6:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Parikh Anand Kiran

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/19/26 9:45:04 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Parikh Anand Kiran

    3 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/19/26 9:44:11 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Donenberg Phillip B.

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/17/26 5:01:24 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Sensei Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $5.00

    6/2/25 8:54:54 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Sensei Biotherapeutics with a new price target

    Stephens initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $5.00

    5/14/24 8:02:37 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler reiterated coverage on Sensei Biotherapeutics with a new price target

    Piper Sandler reiterated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $10.00 from $12.00 previously

    3/10/22 10:13:48 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    SEC Filings

    View All

    SEC Form D filed by Sensei Biotherapeutics Inc.

    D - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    3/4/26 3:52:51 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    2/18/26 8:45:53 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Sensei Biotherapeutics Inc.

    8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    2/13/26 5:29:45 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Leadership Updates

    Live Leadership Updates

    View All

    Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro

    11/14/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month

    8/6/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide

    5/9/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Financials

    Live finance-specific insights

    View All

    Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The

    2/18/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Adopts Stockholder Rights Agreement

    BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i

    3/7/23 5:15:00 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights

    - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash runway at least into first half 2024 BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next

    11/9/21 8:54:48 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    3/7/24 6:00:48 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    2/13/24 5:34:37 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Sensei Biotherapeutics Inc.

    SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    11/3/23 5:03:47 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care